Digg It - Business

To survive in a competitive global environment, an organization must provide targeted customers more value than its competitors, as customer value is the difference between all the benefi

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ts derived from a total product/service and all the costs of acquiring those benefits. For instance, owning a car can provide a number of benefits, including flexible transportation, imag

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

, status, pleasure, comfort, and even companionship. However, securing these benefits requires paying for the car, gasoline, insurance, maintenance, and parking fees, as well as risking i

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

jury from an accident, adding to environmental pollution, and dealing with traffic jams and other frustrations. It is the difference between the total benefits and the total costs that co

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

nstitutes customer value. Thus, providing superior customer value requires the organization to do a better job of anticipating and reacting to customer needs than the competitor does.

Ho

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ever, providing superior value and anticipating today's evolving consumer needs requires deep understanding of the emerging consumer networks, which in turn requires thorough understandin

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

of the behavioral principles that guide the different acceptance levels of alternative distribution channels. Although the unquestionable outcomes of September 11th are still discussed a

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

round the globe, the shift of the public's focus from privacy issues to safety guidelines and the overwhelming acceptance of new technology uses, have considerably altered the scene of op

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

rations. Just as in the traditional product cycle, private information is now circulated as the new commodity that has to accompany the individual and reveal as much classified data as po

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

sible. Under these exchanged guidelines, people have to alter their attitudes towards government invasion and accept unanimously the American principle that 'if you have nothing to hide,

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

hen you have nothing to be afraid of'. Security is the exchanged value in this information marketplace, where the airplane passenger has to surrender his dignity at the security officer's

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

table. But is the market/society able and willing to respond?

The outcomes of few research findings indicate that while anonymity is preferred, the fear principle still governs the ulti

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ate decision and directs the person to reveal as much information as possible, without questioning the use of the acquired information, or the force that directs the whole process. Everyt

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

ing is conducted in the name of a 'greater good'. The passengers' market in this example, accepts the circulation of information without disputing its usefulness and in airport facilities

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

, customer value increases when the passenger calculates the possible outcome of the distributed information. Circulation of information in this example is not just a simple procedure in

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

specific distribution channel, but has become a part of the actual service offered to the public. Keeping information hidden can cause a major crisis, thus people operate under the influ

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

nce of group norms and the pressure of guilt. The redefined safe zone is strengthened by the argument that privacy is a very small price to pay in exchange to security.

But in many parts

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

of the world, airport passengers become reluctant to release private information without first examining if there is a dignity issue involved. More and more traveling markets have come t

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

realize that even when the circulation processes of information are not going to affect directly their lives there is still the issue of personal rights and privacy. The present choices

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

f this market will ultimately be reflected in the future consequences of passengers' tolerance levels, although certainly no one is pleased staying inside this minimum interference utopia

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/44713/diggit-Putting-Security-at-Risk.html">Putting Security at Risk</a>

BB link (for phorums):
[url=http://www.diggit.org.ua/article/44713/diggit-Putting-Security-at-Risk.html]Putting Security at Risk[/url]

There are many reasons why executives, business owners and others put off learning and implementing Cost Benefit Analysis in their businesses. Some of the reasons are listed below. You can gain the advantage over these by understanding the real truths of this powerful, decision-making tool.

A rule of thumb is that idea generation and motivation are inversely proportional to the number of layers between creator and decision maker. So if an individual has to push the idea past one gatekeeper, then:

It's a smart career move to always be networking, no matter what's going on for you professionally. If you don't need help at this time, build-up your networking power by helping others.

Tags

Links

Digg It - Putting Security at Risk

Related Articles: